Netupitant/palonosetron

Netupitant/palonosetron
Combination of
NetupitantNK1 receptor antagonist
Palonosetron5-HT3 receptor antagonist
Names
Trade namesAkynzeo
Clinical data
Main usesChemotherapy-induced nausea and vomiting[1]
Side effectsHeadache, constipation, tiredness[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
    Routes of
    use    		By mouth, intravenous
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa614053
    Legal
    License data
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only) [5]
    • US: ℞-only [6]
    • EU: Rx-only [2]
    • In general: ℞ (Prescription only)

    Netupitant/palonosetron, sold under the brand name Akynzeo, is a combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting.[1] It is taken by mouth.[1] It is used with dexamethasone.[1]

    Common side effects include headache, constipation, and tiredness.[2] The dose does not need to be adjusted in those with mild to moderate liver or kidney problems.[1] Use is not recommended in pregnancy.[7] Netupitant is an NK1 receptor blocker and palonosetron is a 5-HT3 receptor blocker.[2]

    The combination was approved for medical use in the United States in 2014 and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £70 a dose as of 2021.[7] In the United States this amount costs about 680 USD.[8]

    Medical use

    Dosage

    The typical dose is one capsule a hour before chemotherapy.[2] This contains 300 mg of netupitant and 0.5 mg of palonosetron.[1]

    There is an intravenous version that contains fosnetupitant and palonosetron.[9][6]

    Contraindications

    Netupitant/palonosetron may be contraindicated during pregnancy.[10][3][4]

    Side effects

    The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness.[6] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[10]

    Interactions

    Further information: Netupitant § Interactions, and Palonosetron § Interactions

    Pharmacology

    Further information: Netupitant § Pharmacology, and Palonosetron § Pharmacology

    History

    Netupitant/palonosetron was approved for use in the United States in October 2014.[11] It was approved for use in the European Union in May 2015.[2] The intravenous version was approved in the United States in April 2018.[12][9]

    References

    1. 1 2 3 4 5 6 7 "Netupitant/Palonosetron Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 12 November 2021.
    2. 1 2 3 4 5 6 7 "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
    3. 1 2 3 "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 December 2019. Retrieved 19 March 2020.
    4. 1 2 "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
    5. ↑ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 11 February 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
    6. 1 2 3 "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020.
    7. 1 2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 456. ISBN 978-0857114105.
    8. ↑ "Akynzeo Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 12 November 2021.
    9. 1 2 "Drug Trials Snapshots: Akynzeo". U.S. Food and Drug Administration (FDA). 11 May 2018. Archived from the original on 24 January 2020. Retrieved 19 March 2020.
    10. 1 2 Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.{{cite book}}: CS1 maint: unrecognized language (link)
    11. ↑ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718". U.S. Food and Drug Administration (FDA). 7 November 2014. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
    12. ↑ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection". U.S. Food and Drug Administration (FDA). 31 May 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.